Amadori glycated proteins: Role in production of autoantibodies in diabetes mellitus and effect of inhibitors on non-enzymatic glycation

Aging and Disease

Volumn 4, Issue 1, 2013, Pages 50-56

  Ansari, Nadeem A ^a   Dash, Debabrata ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Amadori products; Antibodies; Diabetes complications; Lysine rich proteins

Indexed keywords

EID: 84902379111     PISSN: None     EISSN: 21525250     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Horvat S, Jakas A (2004). Peptide and amino acid glycation: new insights into the Maillard reaction. J Pept Sci, 10: 119-137.
2. Lapolla A, Traldi P, Fedele D (2005). Importance of measuring products of non-enzymatic glycation of proteins. Clin Biochem, 38: 103-115.
3. Armbruster DA (1987). Fructosamine: structure, analysis and clinical usefulness. Clin Chem, 33: 2153-2163.
4. Yaylayan VA, Huyghues-Despointes A (1994). Chemistry of Amadori rearrangement products: analysis, synthesis, kinetics, reactions, and spectroscopic properties. Crit Rev Food Sci, 34: 321.
5. Turk Z (2001). Glycation and complications of diabetes. Diabetol Croatica, 30: 49.
6. Thornalley PJ, Battah S, Ahmed N (2003). Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J, 375: 581-592.
7. Singh R, Barden A, Mori T, Beilin L (2001). Advanced glycation end-products: a review. Diabetologia, 44: 129.
8. Watkins NG, Thorpe SR, Baynes JW (1985). Glycation of amino groups in protein. J Biol Chem, 260: 10629-10636.
9. Rasheed Z, Kumar L, Abbas S, Prasad I, Ansari NA, Ahmad R (2009). Advanced glycation end-products (AGEs) damaged IgG, a target for circulating autoantibodies in patients with type 1 diabetes mellitus. Open Glycosci, 2: 1-8.
10. Menini T, Gugliucci A, Sodahlon YK, Stahl AJC, Blickle JF, Brogard JM (1993). Glycated immunoglobulin M in diabetic patients. Ann Biol Chem, 50: 887-891.
11. Ledl F, Schleicher E (1990). The Maillard reaction in food and in the human body. Angew Chem Int Ed Engl, 29: 565.
12. Munch G, Schicktanz D, Behme A, Gerlach M, Riederer P, Palm D et al (1999). Amino acid specificity of glycation and protein-AGE crosslinking reactivities determined with a dipeptide SPOT library. Nat Biotechnol, 17: 1006.
13. Acharya AS, Manning JM (1980). Amadori rearrangement of glyceraldehyde-hemoglobin Schiff base adducts. J Biol Chem, 255: 7218-7224.
14. Frolov A, Singer D, Hoffmann R (2006). Site-specific synthesis of Amadori-modified peptides on solid phase. J Peptide Sci, 12: 389-395.
15. Jobst K, Lakattos A, Horvath A (1991). Glycohistones in diabetic human liver. Clin Chim Acta, 200: 231-232.
16. Schalkwijk CG, Ligtvoet N, Twaafhoven H, Jager A, Blaauwgeers HGT, Schlingemann RO et al (1999). Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy and localization in retinal capillaries. Diabetes, 48: 2446-2453.
17. Schalkwijk CG, Chaturvedi N, Twaafhoven H, Van Hinsbergh VW, Stehouwer CD (2002). Amadori albumin correlates with microvascular complications and precedes nephropathy in type 1 diabetes. Eur J Clin Invest, 32: 500-556.
18. McCance DR, Dyer DG, Dunn JA, Bailie KE, Thorpe SR, Baynes JW et al (1993). Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest, 91: 2470-2478.
19. Cohen MP, Ziyadeh FN (1994). Amadori glucose adducts modulate mesangial cell growth and collagen gene expression. Kidney Int, 45: 475-484.
20. Sakai H, Jinde K, Suzuki D, Yagame M, Nomoto Y (1996). Localization of glycated proteins in the glomeruli of patients with diabetic nephropathy. Nephrol Dial Transplant, 11: 66-71.
21. Clements Jr RS, Robison Jr, WG, Cohen MP (1998). Anti-glycated albumin therapy ameliorates early retinal microvascular pathology in db/db mice. J Diab Complic, 12: 28-33.
22. Kalia K, Sharma S, Mistry K (2004). Non-enzymatic glycosylation of immunoglobulins in diabetic nephropathy. Clin Chim Acta, 347: 169-176.
23. Jaleel A, Halvatsiotis P, Williamson B (2005). Identification of Amadori-modified plasma proteins in type 2 diabetes and the effect of short-term intensive insulin treatment. Diabetes Care, 28: 645-652.
24. Cohen MP, Ziyadeh FN, Chen S (2006). Amadori-Modified Glycated Serum Proteins and Accelerated Atherosclerosis in Diabetes: Pathogenic and Therapeutic Implications. J Lab Clin Med, 147: 211-219.
25. Monnier VM, Sell DR, Dai Z, Nemet I, Collard F, Zhang J (2008). The role of the Amadori product in complications of diabetes. Ann NY Acad Sci, 1126: 81-88.
26. Ansari NA, Moinuddin, Alam K, Ali A (2009). Preferential recognition of Amadori-rich lysine residues by serum antibodies in diabetes mellitus: Role of protein glycation in the disease process. Human Immunol, 70: 417-424.
27. Ansari NA, Moinuddin, Ali R (2011). Physico-chemical analysis of poly-L-lysine: An insight into the changes induced in lysine residues of proteins upon modification with glucose. IUBMB Life, 63: 26-29.
28. Sookwong P, Nakagawa K, Fujita I, Shoji N, Miyazawa T (2011). Amadori-glycated phosphatidylethanolamine, a potential marker for hyperglycemia, in streptozotocin-induced diabetic rats. Lipids, 46: 943-952.
29. Reddy S, Bichler J, Wells-Knecht KJ, Thorpe SR, Baynes JW (1995). Nepsilon- (carboxymethyl) lysine is a dominant advanced glycation end product (age) antigen in tissue proteins. Biochemistry, 43: 10872-10878.
30. Myint T, Hoshi S, Ookawara T, Miyazawa N, Suzuki K, Taniguchi N (1995). Immunological detection of glycated proteins in normal and streptozotocin-induced diabetic rats using anti hexitol-lysine IgG. Biochim Biophys Acta, 1271: 73-79.
31. Araki N, Shibayama R, Ejima Y, Nagai R, Araki T, Saya H et al (2001). Study of autoantibodies against advanced glycation endproducts of the Maillard reaction. Intl Cong Series, 123: 49-58.
32. Khan MWA, Qadrie ZL, Khan WA (2010). Antibodies against gluco-oxidatively modified human serum albumin detected in diabetes-associated complications. Int Arch Allergy Immunol, 153: 207-214.
33. Fu M-X, Wells-knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW (1994). Glycation, glycoxidation and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes, 43: 676-683.
34. Jakus V, Hrnciarova M, Carsky J, Krahulec B, Rietbrock N (1999). Inhibition of nonenzymatic protein glycation and lipid peroxidation by drugs with anti-oxidant activity. Life Sci, 65: 1991-1993.
35. Jafarnejad A, Bathaie SJ, Nakhjavani M, Hassan MJ, Banasadegh S (2008). The improvement effect of L-lysine as a chemical chaperone on STZ-induced diabetic rats, protein structure and function. Diabetes/Metab Res Rev, 24: 64-73.
36. Sims HM, Birdwell AL, O'Reilley KE, Bwashi A, Wing BD (2008). Inhibition of protein glycation with varying concentrations of lysine. The FASEB J, 22: 1123.15.
37. Adrover M, Vilanova B, Frau J, Munoz F, Donoso F (2008). The pyridoxamine action on Amadori compounds: A reexamination of its scavenging capacity and chelating effect. Bioorg Med Chem, 16: 5557-5569.
38. Thornalley PJ, Rabbani N (2010). Therapy: Vitamin B(6), B(9) and B(12) in diabetic nephropathy-beware. Nat Rev Endocrinol, 6: 477-478.
39. Goh SY, Cooper ME (2008). Clinical review: the role of advanced glycation endproducts in progression and complications of diabetes. J Clin Endocrinol Metab, 93: 1143-1152.
40. Schalkwijk CG, Miyata T (2012). Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics. Amino Acids, 42: 1193-1204.
41. Gugliucci A, Bastos DHM, Schulze J, Souza MFF (2009). Caffeic and cholorogenic acids in Ilex paraguariensis are the main inhibitors of AGE generation by methylglyoxal in model proteins. Fitoterapia, 80: 339-344.
42. Ahmad MS, Pischetsrieder M, Ahmed N (2007). Aged garlic extract and S-allyl cysteine prevent formation of advanced glycation endproducts. Eur J Pharmacol, 56: 32-38.
43. Nagasawa T, Tabata N, Ito Y, Nichigawa N, Aiba Y, Kitts DD (2003). Inhibition of glycation reaction in tissue protein incubations by water soluble rutin derivative. Mol Cell Biochem, 249: 3-10.
44. Cervantes-Laurean D, Schramm DD, Jacobson, EL, Halaweish I, Bruckner GG, Boissoneault GA (2006). Inhibition of advanced glycation end product formation on collagen by rutin and its metabolites. J Nutri Biochem, 17: 531-540
45. Pashikanti S, Alba DR, Boissonneault GA, Cervantes-Laurean D (2010). Rutin Metabolites: Novel inhibitors of nonoxidative advanced glycation end products. Free Radic Biol Med, 48: 656-663.
46. Liu H, Liu H, Wang W, Khoo C, Taylor J, Gu L (2011). Cranberry phytochemicals inhibit glycation of human hemoglobin and serum albumin by scavenging reactive carbonyls. Food Funct, 2: 475-482.
47. Singh S, Bhattacharya J, Datta H, Dasgupta AK (2009). Anti-glycation activity of gold nanoparticles. Nanomedicine: Nanotech Biol Med, 5: 21-29.
48. Seneviratne C, Narayanan R, Liu W, Dain J (2012). The in vitro inhibition effect of 2nm gold nanoparticles on non-enzymatic glycation of human serum albumin. Biochem Biophys Res Commun, 422: 447-454.
49. Kim J, Hong C, Koo Y, Choi H, Lee K (2012). Anti-glycation effect of gold nanoparticles on collagen. Biol Pharm Bull, 35: 260-264.
50. Sheikpranbabu S, Kalishwaralal K, Lee K, Vaidyanathan R, Eom SH, Gurunathan S (2010). The inhibition of advanced glycation end-products-induced retinal vascular permeability by silver nanoparticles. Biomaterials, 31: 2260-2271.